- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Lisa Astor | Authors
Articles
Weight-Based Chemotherapy Dosing May Improve Outcomes in Obese Populations With CRC
July 16, 2021
Findings from the OCTOPUS Consortium of trial data indicated that weight-based chemotherapy dosing may improve outcomes for obese patients with colorectal cancer.
Relapsed/Refractory DLBCL Has Extended Response Duration With Naratuximab Emtansine Plus Rituximab
June 14, 2021
Clinical activity with the combination of naratuximab emtansine plus rituximab was observed in patients with relapsed or refractory diffuse large B-cell lymphoma.
Lifileucel Continues to Show Durable Responses in Advanced Melanoma
June 06, 2021
With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy
De-escalated Neoadjuvant Trastuzumab/Pertuzumab Induced Sufficient Responses in HER2+/HR– Breast Cancer
June 06, 2021
With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.
Traditional Resistance to EGFR Inhibitors May Not Effect Responses With Amivantamab/Lazertinib in EGFR+ NSCLC
June 05, 2021
Some patients who progressed on osimertinib had a response to therapy with amivantamab and lazertinib, and these were seen regardless of known resistance mechanisms to EGFR inhibitors.
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma
April 11, 2021
Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.
Platinum-Sensitive Relapsed Ovarian Cancer Derives Benefit from Maintenance Olaparib, Regardless of Tumor BRCA Status
March 24, 2021
Results of prospective, open-label trial of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer continued to demonstrate efficacy of the PARP inhibitor in this setting.
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer
March 20, 2021
An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.
In B-Cell NHL, Off-the-Shelf NK Immunotherapy Shows Promise When Used With Chemotherapy and ASCT
February 19, 2021
Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.
Phase 3 Data Support Enfortumab Vedotin Benefit in Previously Treated Urothelial Carcinoma
February 13, 2021
Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.